ASG. Aurora Spine Corp

Aurora Spine Announces Receipt of Loan Proceeds Under Paycheck Protection Program

Aurora Spine Announces Receipt of Loan Proceeds Under Paycheck Protection Program

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES

CARLSBAD, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSX VENTURE:ASG) (OTCQB:ASAPF) announced today that it has received loan proceeds of $350,140 (“PPP Loan”) under the Second Draw Paycheck Protection Program. The Paycheck Protection Program (“PPP”) was established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) in order to enable small businesses to pay employees during the coronavirus crisis and provides loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the PPP is eligible to be forgiven provided that the borrower uses the loan proceeds during the eight week or 24 week period after receiving them and provided that the proceeds are used for payroll costs (including benefits), rent, mortgage interest, utility costs and worker protection costs related to COVID-19.

Principal and interest payments on any unforgiven portion of the PPP Loan will be deferred for ten months and will accrue interest at a fixed annual rate of 1%. Additionally, the remaining PPP Loan balance will carry a five-year maturity date. There is no prepayment penalty on the PPP Loan.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant and pain management markets through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at or .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the PPP Loan and its potential forgiveness or repayment. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

For more information, please contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Clouse

Chief Financial Officer

(760) 424-2004

Adam Lowensteiner

LYTHAM PARTNERS, LLC

Phoenix | New York

Telephone: 646-829-9700



EN
24/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurora Spine Corp

Aurora Spine Corp: 2 directors

Two Directors at Aurora Spine Corp sold/bought 825,000 shares at 0.240USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

Aurora Spine Corporation Celebrates Second Anniversary of Initial Impl...

Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World’s First Bone Density Matched DEXA-C Cervical Interbody Fusion Device CARLSBAD, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants announced today that it has completed the second full year of implantation of the world’s first patient-bone-density matched interbody device, the cervical interbody DEXA-C. Trent Northcutt, CEO and President at Aurora Spine said, "It's a signifi...

 PRESS RELEASE

Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Match...

Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office CARLSBAD, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology. Aur...

 PRESS RELEASE

The United States Patent Office Grants New Patent for Aurora Spine’s T...

The United States Patent Office Grants New Patent for Aurora Spine’s Translucent GhostTube™ Surgical Operating Tube CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled “Hybrid Radiolucent Surgical Operating Tube”. Aurora Spine’s Ghost Tube™ was designed to provide superior anchoring with a translucent thermoplastic body and non-slipping tita...

 PRESS RELEASE

AURORA SPINE ANNOUNCES ATTENDANCE AT NORTH AMERICAN NEUROMODULATION SO...

AURORA SPINE ANNOUNCES ATTENDANCE AT NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) ANNUAL MEETING CARLSBAD, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be participating in the North American Neuromodulation Society (“NANS”) Annual Meeting from January 18-21 in Las Vegas, Nevada. The NANS Annual Meeting is a prominent medical conference that brings together healthcare professionals, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch